1	SENATE FLOOR VERSION			
0	February 17, 2022			
2				
3	SENATE BILL NO. 1338 By: Bullard			
4				
5				
6	An Act relating to the Uniformed Controlled Dangerous Substances Act; amending 2 O.S. 2021, Section 3-601,			
7	which relates to the Oklahoma Industrial Hemp Remediation Program; modifying definition; amending			
8	63 O.S. 2021, Section 2-101, as last amended by Section 1, Chapter 222, O.S.L. 2021, which relates to			
9	definitions; modifying definition; amending 63 O.S. 2021, Section 427.2, as last amended by Section 4,			
10	Chapter 584, O.S.L. 2021, which relates to definitions; modifying definition; updating statutory			
11	language; and providing an effective date.			
12				
13				
14	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:			
15	SECTION 1. AMENDATORY 2 O.S. 2021, Section 3-601, is			
16	amended to read as follows:			
17	Section 3-601. A. This act shall be known and may be cited as			
18	the "Oklahoma Industrial Hemp Remediation Program".			
19	B. As used in the Oklahoma Industrial Hemp Remediation Program,			
20	the following words and terms, and any derivative of such words or			
21	terms, shall have the following meanings, unless the context clearly			
22	indicates otherwise:			
23	1. "Cannabis" means a genus of flowering plants in the family			

Cannabaceae of which Cannabis sativa is a species and Cannabis

- 1 | indica and Cannabis ruderalis are subspecies thereof. Cannabis
- 2 refers to any form of the plant in which the delta-9
- 3 | tetrahydrocannabinol concentration on a dry-weight basis has not yet
- 4 been determined;
- 5 | 2. "Certified laboratory" means the laboratory operated by the
- 6 Oklahoma Department of Agriculture, Food, and Forestry or a
- 7 | laboratory located in Oklahoma that is certified by the Department;
- 8 3. "Commercial sale" means the sale of a product in the stream
- 9 of commerce at retail, at wholesale or on the Internet;
  - 4. "CSA" means the federal Controlled Substances Act;
- 11 5. "DEA" means the United States Drug Enforcement
- 12 | Administration;

- 6. "Department" means the Oklahoma Department of Agriculture,
- 14 Food, and Forestry;
- 7. "Hemp" means the plant Cannabis sativa L. and any part of
- 16 | such plant including, but not limited to, the seeds and all
- 17 derivatives, extracts, cannabinoids, isomers, acids, salts and salts
- 18 of isomers, whether growing or not, and grown from a certified seed
- 19 | with a delta-9 or delta-8 tetrahydrocannabinol concentration of not
- 20 more than three-tenths of one percent (0.3%) on a dry-weight basis.
- 21 Hemp and hemp-derived cannabinoids, including cannabidiol, shall be
- 22 | considered an agricultural commodity and not a controlled substance
- 23 due to the presence of hemp or hemp-derived cannabinoids;

- 8. "Hemp Program" means the Oklahoma Industrial Hemp Remediation Program and any final ruling from the USDA;
  - 9. "Law enforcement" means any federal, state or local agencies responsible for maintaining public order and enforcing the law;
  - 10. "License" means the written authorization by the Department for any person to grow, process, handle or transport certified seeds or hemp in this state;
  - 11. "Person" means any natural person or any corporation, general partnership, limited partnership, limited liability partnership, limited liability company, trust, estate, charitable organization, joint stock company, joint venture, association or any other business or similar organization recognized by the state;
  - 12. "Processor" means any person who is licensed by the Department to process hemp in this state;
    - 13. "State" means the State of Oklahoma;
  - 14. "THC" means delta-9 tetrahydrocannabinol, which is a psychoactive component in cannabis plants;
  - 15. "Tracking software" means software that is approved by the Department and is capable of transparently tracking hemp in any state or form whatsoever including, but not limited to, a certified seed, any stage of growth, processing or handling, and any hemp product; and
    - 16. "USDA" means the United States Department of Agriculture.

- C. In the event that any hemp produced under the Hemp Program is determined by testing results to be noncompliant with the Hemp Program, the person holding the license for the noncompliant hemp may request approval from the Department to remediate the noncompliant hemp.
- D. If the Department approves the remediation of the noncompliant hemp, the person holding the license shall promptly have the noncompliant hemp extracted by a licensed processor into concentrated form and the hemp concentrate shall be sampled by a certified laboratory for compliance with USDA levels for THC in concentrated form.
- E. If the samples of the hemp concentrate are below USDA levels for THC, the hemp concentrate shall be compliant as a hemp product with the Hemp Program and may be used in commercial sales.
- F. If the samples of the hemp concentrate are above the USDA levels for THC, the hemp concentrate shall be noncompliant with the Hemp Program and shall be destroyed in accordance with the CSA and DEA regulations found at 21 C.F.R., Section 1317.15, as enforced by federal, state and local law enforcement. The person holding the license for the noncompliant hemp concentrate shall promptly notify the Department and USDA of its intent to destroy the noncompliant hemp concentrate and verify destruction by submitting required documentation using the tracking software.

1	SECTION 2.	AMENDATORY	63 O.S.	2021, Sect	tion 2-101, as
2	last amended by	Section 1, Cha	pter 222, 0	.S.L. 2021,	is amended to
3	read as follows:				

Section 2-101. As used in the Uniform Controlled Dangerous Substances Act:

- 1. "Administer" means the direct application of a controlled dangerous substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient, animal or research subject by:
  - a. a practitioner (or, in the presence of the practitioner, by the authorized agent of the practitioner), or
  - b. the patient or research subject at the direction and in the presence of the practitioner;
- 2. "Agent" means a peace officer appointed by and who acts on behalf of the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control or an authorized person who acts on behalf of or at the direction of a person who manufactures, distributes, dispenses, prescribes, administers or uses for scientific purposes controlled dangerous substances but does not include a common or contract carrier, public warehouser or employee thereof, or a person required to register under the Uniform Controlled Dangerous Substances Act;

3. "Board" means the Advisory Board to the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;

- 4. "Bureau" means the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
- 5. "Coca leaves" includes cocaine and any compound,
  manufacture, salt, derivative, mixture or preparation of coca
  leaves, except derivatives of coca leaves which do not contain
  cocaine or ecgonine;
- 6. "Commissioner" or "Director" means the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
- 7. "Control" means to add, remove or change the placement of a drug, substance or immediate precursor under the Uniform Controlled Dangerous Substances Act;
- 8. "Controlled dangerous substance" means a drug, substance or immediate precursor in Schedules I through V of the Uniform Controlled Dangerous Substances Act or any drug, substance or immediate precursor listed either temporarily or permanently as a federally controlled substance. Any conflict between state and federal law with regard to the particular schedule in which a substance is listed shall be resolved in favor of state law;
- 9. "Counterfeit substance" means a controlled substance which, or the container or labeling of which without authorization, bears the trademark, trade name or other identifying marks, imprint, number or device or any likeness thereof of a manufacturer,

- 1 distributor or dispenser other than the person who in fact 2 manufactured, distributed or dispensed the substance;
  - 10. "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of a controlled dangerous substance or drug paraphernalia, whether or not there is an agency relationship;
  - 11. "Dispense" means to deliver a controlled dangerous substance to an ultimate user or human research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling or compounding necessary to prepare the substance for such distribution.
- "Dispenser" is a practitioner who delivers a controlled dangerous substance to an ultimate user or human research subject;
  - 12. "Distribute" means to deliver other than by administering or dispensing a controlled dangerous substance;
  - 13. "Distributor" means a commercial entity engaged in the distribution or reverse distribution of narcotics and dangerous drugs and who complies with all regulations promulgated by the federal Drug Enforcement Administration and the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
    - 14. "Drug" means articles:
      - recognized in the official United States Pharmacopeia,
        official Homeopathic Pharmacopoeia of the United

States, or official National Formulary, or any supplement to any of them,

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

- b. intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals,
- c. other than food, intended to affect the structure or any function of the body of man or other animals, and
- d. intended for use as a component of any article specified in this paragraph;

provided, however, the term "drug" does not include devices or their components, parts or accessories;

- 15. "Drug-dependent person" means a person who is using a controlled dangerous substance and who is in a state of psychic or physical dependence, or both, arising from administration of that controlled dangerous substance on a continuous basis. Drug dependence is characterized by behavioral and other responses which include a strong compulsion to take the substance on a continuous basis in order to experience its psychic effects, or to avoid the discomfort of its absence;
- 20 16. "Home care agency" means any sole proprietorship,
  21 partnership, association, corporation, or other organization which
  22 administers, offers, or provides home care services, for a fee or
  23 pursuant to a contract for such services, to clients in their place
  24 of residence;

17. "Home care services" means skilled or personal care services provided to clients in their place of residence for a fee;

1

2

3

4

5

6

7

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- "Hospice" means a centrally administered, nonprofit or for-18. profit, medically directed, nurse-coordinated program which provides a continuum of home and inpatient care for the terminally ill patient and the patient's family. Such term shall also include a centrally administered, nonprofit or for-profit, medically directed, nurse-coordinated program if such program is licensed pursuant to the provisions of the Uniform Controlled Dangerous Substances Act. A hospice program offers palliative and supportive care to meet the special needs arising out of the physical, emotional and spiritual stresses which are experienced during the final stages of illness and during dying and bereavement. This care is available twentyfour (24) hours a day, seven (7) days a week, and is provided on the basis of need, regardless of ability to pay. "Class A" Hospice refers to Medicare-certified hospices. "Class B" refers to all other providers of hospice services;
- 19. "Imitation controlled substance" means a substance that is not a controlled dangerous substance, which by dosage unit appearance, color, shape, size, markings or by representations made, would lead a reasonable person to believe that the substance is a controlled dangerous substance. In the event the appearance of the dosage unit is not reasonably sufficient to establish that the substance is an "imitation controlled substance", the court or

authority concerned should consider, in addition to all other
factors, the following factors as related to "representations made"
in determining whether the substance is an "imitation controlled
substance":

- a. statements made by an owner or by any other person in control of the substance concerning the nature of the substance, or its use or effect,
- b. statements made to the recipient that the substance may be resold for inordinate profit,
- c. whether the substance is packaged in a manner normally used for illicit controlled substances,
- d. evasive tactics or actions utilized by the owner or person in control of the substance to avoid detection by law enforcement authorities,
- e. prior convictions, if any, of an owner, or any other person in control of the object, under state or federal law related to controlled substances or fraud, and
- f. the proximity of the substances to controlled dangerous substances;
- 20. "Immediate precursor" means a substance which the Director has found to be and by regulation designates as being the principal compound commonly used or produced primarily for use, and which is an immediate chemical intermediary used, or likely to be used, in

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

the manufacture of a controlled dangerous substance, the control of which is necessary to prevent, curtail or limit such manufacture;

- 21. "Laboratory" means a laboratory approved by the Director as proper to be entrusted with the custody of controlled dangerous substances and the use of controlled dangerous substances for scientific and medical purposes and for purposes of instruction;
- 22. "Manufacture" means the production, preparation, propagation, compounding or processing of a controlled dangerous substance, either directly or indirectly by extraction from substances of natural or synthetic origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacturer" includes any person who packages, repackages or labels any container of any controlled dangerous substance, except practitioners who dispense or compound prescription orders for delivery to the ultimate consumer;
- 23. "Marijuana" means all parts of the plant Cannabis sativa

  L., whether growing or not; the seeds thereof; the resin extracted

  from any part of such plant; and every compound, manufacture, salt,

  derivative, mixture or preparation of such plant, its seeds or

  resin, but shall not include:
  - a. the mature stalks of such plant or fiber produced from such stalks,

1 b. oil or cake made from the seeds of such plant, 2 including cannabidiol derived from the seeds of the 3 marijuana plant, any other compound, manufacture, salt, derivative, 4 C. 5 mixture or preparation of such mature stalks (except the resin extracted therefrom), including cannabidiol 6 derived from mature stalks, fiber, oil or cake, 7 d. the sterilized seed of such plant which is incapable 8 9 of germination, for any person participating in a clinical trial to е. 10 administer cannabidiol for the treatment of severe 11 12 forms of epilepsy pursuant to Section 2-802 of this title, a drug or substance approved by the federal 13 Food and Drug Administration for use by those 14 15 participants, f. for any person or the parents, legal guardians or 16 caretakers of the person who have received a written 17 certification from a physician licensed in this state 18 that the person has been diagnosed by a physician as 19 having Lennox-Gastaut syndrome, Dravet syndrome, also 20

known as severe myoclonic epilepsy of infancy, or any

other severe form of epilepsy that is not adequately

treated by traditional medical therapies, spasticity

due to multiple sclerosis or due to paraplegia,

21

22

23

intractable nausea and vomiting, appetite stimulation with chronic wasting diseases, the substance cannabidiol, a nonpsychoactive cannabinoid, found in the plant Cannabis sativa L. or any other preparation thereof, that has a tetrahydrocannabinol concentration of not more than three-tenths of one percent (0.3%) and that is delivered to the patient in the form of a liquid,

- g. any federal Food-and-Drug-Administration-approved drug or substance, or
- h. industrial hemp, from the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 or delta-8 tetrahydrocannabinol concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis which shall only be grown pursuant to the Oklahoma Industrial Hemp Program and may be shipped intrastate and interstate;
- 24. "Medical purpose" means an intention to utilize a controlled dangerous substance for physical or mental treatment, for diagnosis, or for the prevention of a disease condition not in violation of any state or federal law and not for the purpose of satisfying physiological or psychological dependence or other abuse;
- 25. "Mid-level practitioner" means an Advanced Practice
  Registered Nurse as defined and within parameters specified in

- Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified animal euthanasia technician as defined in Section 698.2 of Title 59 of the Oklahoma Statutes, or an animal control officer registered by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control under subsection B of Section 2-301 of this title within the parameters of such officer's duties under Sections 501 through 508 of Title 4 of the Oklahoma Statutes;
  - 26. "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
    - a. opium, coca leaves and opiates,

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- a compound, manufacture, salt, derivative or preparation of opium, coca leaves or opiates,
- c. cocaine, its salts, optical and geometric isomers, and salts of isomers,
- d. ecgonine, its derivatives, their salts, isomers and salts of isomers, and
- e. a substance, and any compound, manufacture, salt,

  derivative or preparation thereof, which is chemically

  identical with any of the substances referred to in

  subparagraphs a through d of this paragraph, except

  that the words "narcotic drug" as used in Section 2
  101 et seq. of this title shall not include

decocainized coca leaves or extracts of coca leaves,

which extracts do not contain cocaine or ecgonine;

- 27. "Opiate" or "opioid" means any Schedule II, III, IV or V substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. The terms do not include, unless specifically designated as controlled under the Uniform Controlled Dangerous Substances Act, the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its salts (dextromethorphan). The terms do include the racemic and levorotatory forms;
- 28. "Opium poppy" means the plant of the species Papaver somniferum L., except the seeds thereof;
  - 29. "Peace officer" means a police officer, sheriff, deputy sheriff, district attorney's investigator, investigator from the Office of the Attorney General, or any other person elected or appointed by law to enforce any of the criminal laws of this state or of the United States;
  - 30. "Person" means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership or association, or any other legal entity;
- 22 31. "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing;
  - 32. "Practitioner" means:

1	a. (1) a	a medical doctor or osteopathic physician,
2	(2) a	a dentist,
3	(3) a	a podiatrist,
4	(4) 8	an optometrist,
5	(5) a	a veterinarian,
6	(6) a	a physician assistant or Advanced Practice
7	F	Registered Nurse under the supervision of a
8	1	icensed medical doctor or osteopathic physician,
9	(7) a	a scientific investigator, or
10	(8) a	any other person,
11	licens	sed, registered or otherwise permitted to
12	prescr	ribe, distribute, dispense, conduct research with
13	respec	ct to, use for scientific purposes or administer
14	a cont	crolled dangerous substance in the course of
15	profes	ssional practice or research in this state, or
16	b. a phar	rmacy, hospital, laboratory or other institution
17	licens	sed, registered or otherwise permitted to
18	distri	bute, dispense, conduct research with respect
19	to, us	se for scientific purposes or administer a
20	contro	olled dangerous substance in the course of
21	profes	ssional practice or research in this state;
22	33. "Production	" includes the manufacture, planting,
23	cultivation, growing	g or harvesting of a controlled dangerous
24	substance;	

- 34. "State" means the State of Oklahoma this state or any other state of the United States;
- 35. "Ultimate user" means a person who lawfully possesses a controlled dangerous substance for the person's own use or for the use of a member of the person's household or for administration to an animal owned by the person or by a member of the person's household;
- 36. "Drug paraphernalia" means all equipment, products and materials of any kind which are used, intended for use, or fashioned specifically for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body, a controlled dangerous substance in violation of the Uniform Controlled Dangerous Substances Act including, but not limited to:
  - a. kits used, intended for use, or fashioned specifically for use in planting, propagating, cultivating, growing or harvesting of any species of plant which is a controlled dangerous substance or from which a controlled dangerous substance can be derived,
  - b. kits used, intended for use, or fashioned specifically for use in manufacturing, compounding, converting,

1 producing, processing or preparing controlled dangerous substances, 2 isomerization devices used, intended for use, or 3 C. fashioned specifically for use in increasing the 4 5 potency of any species of plant which is a controlled dangerous substance, 6 d. testing equipment used, intended for use, or fashioned 7 specifically for use in identifying, or in analyzing 9 the strength, effectiveness or purity of controlled dangerous substances, 10 scales and balances used, intended for use, or 11 е. fashioned specifically for use in weighing or 12 measuring controlled dangerous substances, 13 f. diluents and adulterants, such as quinine 14 hydrochloride, mannitol, mannite, dextrose and 15 lactose, used, intended for use, or fashioned 16 specifically for use in cutting controlled dangerous 17 substances, 18 separation gins and sifters used, intended for use, or 19 g. fashioned specifically for use in removing twigs and 20 seeds from, or in otherwise cleaning or refining, 21 marijuana, 22 23

1	h.	blenders, bowls, containers, spoons and mixing devices
2		used, intended for use, or fashioned specifically for
3		use in compounding controlled dangerous substances,
4	i.	capsules, balloons, envelopes and other containers
5		used, intended for use, or fashioned specifically for
6		use in packaging small quantities of controlled
7		dangerous substances,
8	j.	containers and other objects used, intended for use,
9		or fashioned specifically for use in parenterally
10		injecting controlled dangerous substances into the
11		human body,
12	k.	hypodermic syringes, needles and other objects used,
13		intended for use, or fashioned specifically for use in
14		parenterally injecting controlled dangerous substances
15		into the human body,
16	1.	objects used, intended for use, or fashioned
17		specifically for use in ingesting, inhaling or
18		otherwise introducing marijuana, cocaine, hashish or
19		hashish oil into the human body, such as:
20		(1) metal, wooden, acrylic, glass, stone, plastic or
21		ceramic pipes with or without screens, permanent
22		screens, hashish heads or punctured metal bowls,
23		(2) water pipes,
24		(3) carburetion tubes and devices,

1	(4) smoking and carburetion masks,
2	(5) roach clips, meaning objects used to hold burning
3	material, such as a marijuana cigarette, that has
4	become too small or too short to be held in the
5	hand,
6	(6) miniature cocaine spoons and cocaine vials,
7	(7) chamber pipes,
8	(8) carburetor pipes,
9	(9) electric pipes,
10	(10) air-driven pipes,
11	(11) chillums,
12	(12) bongs, or
13	(13) ice pipes or chillers,
14	m. all hidden or novelty pipes, and
15	n. any pipe that has a tobacco bowl or chamber of less
16	than one-half $(1/2)$ inch in diameter in which there is
17	any detectable residue of any controlled dangerous
18	substance as defined in this section or any other
19	substances not legal for possession or use;
20	provided, however, the term "drug paraphernalia" shall not include
21	separation gins intended for use in preparing tea or spice, clamps
22	used for constructing electrical equipment, water pipes designed for
23	ornamentation in which no detectable amount of an illegal substance
24	is found or pipes designed and used solely for smoking tobacco,

1 traditional pipes of an American Indian tribal religious ceremony, or antique pipes that are thirty (30) years of age or older; "Synthetic controlled substance" means a substance: 3 37. a. the chemical structure of which is substantially 4 (1)5 similar to the chemical structure of a controlled dangerous substance in Schedule I or II, 6 which has a stimulant, depressant, or (2) hallucinogenic effect on the central nervous 9 system that is substantially similar to or greater than the stimulant, depressant or 10 hallucinogenic effect on the central nervous 11 12 system of a controlled dangerous substance in Schedule I or II, or 13 with respect to a particular person, which such (3) 14 person represents or intends to have a stimulant, 15 depressant, or hallucinogenic effect on the 16 17 central nervous system that is substantially similar to or greater than the stimulant, 18 depressant, or hallucinogenic effect on the 19 central nervous system of a controlled dangerous 20 substance in Schedule I or II. 21 b. The designation of gamma butyrolactone or any other 22

chemical as a precursor, pursuant to Section 2-322 of

this title, does not preclude a finding pursuant to

23

1		subparagraph a of this paragraph that the chemical is
2		a synthetic controlled substance.
3	С.	"Synthetic controlled substance" does not include:
4		(1) a controlled dangerous substance,
5		(2) any substance for which there is an approved new
6		drug application,
7		(3) with respect to a particular person any
8		substance, if an exemption is in effect for
9		investigational use, for that person under the
10		provisions of Section 505 of the Federal Food,
11		Drug and Cosmetic Act, Title 21 of the United
12		States Code, Section 355, to the extent conduct
13		with respect to such substance is pursuant to
14		such exemption, or
15		(4) any substance to the extent not intended for
16		human consumption before such an exemption takes
17		effect with respect to that substance.
18	d.	Prima facie evidence that a substance containing
19		salvia divinorum has been enhanced, concentrated or
20		chemically or physically altered shall give rise to a
21		rebuttable presumption that the substance is a
22		synthetic controlled substance;
23		

38. "Tetrahydrocannabinols" means all substances that have been chemically synthesized to emulate the tetrahydrocannabinols of marijuana;

- 39. "Isomer" means the optical isomer, except as used in subsections C and F of Section 2-204 of this title and paragraph 4 of subsection A of Section 2-206 of this title. As used in subsections C and F of Section 2-204 of this title, "isomer" means the optical, positional or geometric isomer. As used in paragraph 4 of subsection A of Section 2-206 of this title, the term "isomer" means the optical or geometric isomer;
- 40. "Hazardous materials" means materials, whether solid, liquid or gas, which are toxic to human, animal, aquatic or plant life, and the disposal of which materials is controlled by state or federal guidelines;
- 41. "Anhydrous ammonia" means any substance that exhibits cryogenic evaporative behavior and tests positive for ammonia;
- 42. "Acute pain" means pain, whether resulting from disease, accidental or intentional trauma or other cause, that the practitioner reasonably expects to last only a short period of time. "Acute pain" does not include chronic pain, pain being treated as part of cancer care, hospice or other end-of-life care, or pain being treated as part of palliative care;
- 43. "Chronic pain" means pain that persists beyond the usual course of an acute disease or healing of an injury. "Chronic pain"

may or may not be associated with an acute or chronic pathologic process that causes continuous or intermittent pain over months or years;

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- 44. "Initial prescription" means a prescription issued to a patient who:
  - a. has never previously been issued a prescription for the drug or its pharmaceutical equivalent in the past year, or
  - b. requires a prescription for the drug or its pharmaceutical equivalent due to a surgical procedure or new acute event and has previously had a prescription for the drug or its pharmaceutical equivalent within the past year.

When determining whether a patient was previously issued a prescription for a drug or its pharmaceutical equivalent, the practitioner shall consult with the patient and review the medical record and prescription monitoring information of the patient;

- 45. "Patient-provider agreement" means a written contract or agreement that is executed between a practitioner and a patient, prior to the commencement of treatment for chronic pain using an opioid drug as a means to:
  - a. explain the possible risk of development of physical or psychological dependence in the patient and prevent the possible development of addiction,

1	b.	document the understanding of both the practitioner
2		and the patient regarding the patient-provider
3		agreement of the patient,
4	С.	establish the rights of the patient in association
5		with treatment and the obligations of the patient in
6		relation to the responsible use, discontinuation of
7		use, and storage of opioid drugs, including any
8		restrictions on the refill of prescriptions or the
9		acceptance of opioid prescriptions from practitioners,
10	d.	identify the specific medications and other modes of
11		treatment, including physical therapy or exercise,
12		relaxation or psychological counseling, that are
13		included as a part of the patient-provider agreement,
14	е.	specify the measures the practitioner may employ to
15		monitor the compliance of the patient including, but
16		not limited to, random specimen screens and pill
17		counts, and
18	f.	delineate the process for terminating the agreement,
19		including the consequences if the practitioner has
20		reason to believe that the patient is not complying
21		with the terms of the agreement. Compliance with the
22		"consent items" shall constitute a valid, informed
23		consent for opioid therapy. The practitioner shall be

held harmless from civil litigation for failure to

1 treat pain if the event occurs because of nonadherence by the patient with any of the provisions of the patient-provider agreement;

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

- 46. "Serious illness" means a medical illness or physical injury or condition that substantially affects quality of life for more than a short period of time. "Serious illness" includes, but is not limited to, Alzheimer's disease or related dementias, lung disease, cancer, heart failure, renal failure, liver failure or chronic, unremitting or intractable pain such as neuropathic pain; and
- "Surgical procedure" means a procedure that is performed 47. for the purpose of structurally altering the human body by incision or destruction of tissues as part of the practice of medicine. This term includes the diagnostic or therapeutic treatment of conditions or disease processes by use of instruments such as lasers, ultrasound, ionizing, radiation, scalpels, probes or needles that cause localized alteration or transportation of live human tissue by cutting, burning, vaporizing, freezing, suturing, probing or manipulating by closed reduction for major dislocations or fractures, or otherwise altering by any mechanical, thermal, lightbased, electromagnetic or chemical means.
- 63 O.S. 2021, Section 427.2, as SECTION 3. AMENDATORY 22 last amended by Section 4, Chapter 584, O.S.L. 2021, is amended to 23 read as follows: 24

Section 427.2. As used in the Oklahoma Medical Marijuana and Patient Protection Act:

- 1. "Advertising" means the act of providing consideration for the publication, dissemination, solicitation or circulation, of visual, oral or written communication to induce directly or indirectly any person to patronize a particular medical marijuana business, or to purchase particular medical marijuana or a medical marijuana product. Advertising includes marketing, but does not include packaging and labeling;
  - 2. "Authority" means the Oklahoma Medical Marijuana Authority;
- 3. "Batch number" means a unique numeric or alphanumeric identifier assigned prior to testing to allow for inventory tracking and traceability;
- 4. "Cannabinoid" means any of the chemical compounds that are active principles of marijuana;
- 5. "Caregiver" means a family member or assistant who regularly looks after a medical marijuana license holder whom a physician attests needs assistance;
  - 6. "Child-resistant" means special packaging that is:
    - a. designed or constructed to be significantly difficult for children under five (5) years of age to open and not difficult for normal adults to use properly as defined by 16 C.F.R. 1700.15 (1995) and 16 C.F.R. 1700.20 (1995),

- b. opaque so that the outermost packaging does not allow the product to be seen without opening the packaging material, and
  - c. resealable to maintain its child-resistant effectiveness for multiple openings for any product intended for more than a single use or containing multiple servings;
  - 7. "Clone" means a nonflowering plant cut from a mother plant that is capable of developing into a new plant and has shown no signs of flowering;
    - 8. "Commissioner" means the State Commissioner of Health;
  - 9. "Complete application" means a document prepared in accordance with the provisions set forth in the Oklahoma Medical Marijuana and Patient Protection Act, rules promulgated pursuant thereto, and the forms and instructions provided by the Department including any supporting documentation required and the applicable license application fee;
    - 10. "Department" means the State Department of Health;
- 19 11. "Director" means the Executive Director of the Oklahoma
  20 Medical Marijuana Authority;
  - 12. "Dispense" means the selling of medical marijuana or a medical marijuana product to a qualified patient or the designated caregiver of the patient that is packaged in a suitable container

5

6

7

8

9

10

11

12

13

14

15

16

17

18

21

22

appropriately labeled for subsequent administration to or use by a qualifying patient;

- 13. "Dispensary" means a medical marijuana dispensary, an entity that has been licensed by the Department pursuant to the Oklahoma Medical Marijuana and Patient Protection Act to purchase medical marijuana or medical marijuana products from a licensed medical marijuana commercial grower or medical marijuana processor, sell medical marijuana or medical marijuana products to patients and caregivers as defined under the Oklahoma Medical Marijuana and Patient Protection Act, or sell or transfer products to another dispensary;
- 14. "Edible medical marijuana product" means any medicalmarijuana-infused product for which the intended use is oral
  consumption including, but not limited to, any type of food, drink
  or pill;
- 15. "Entity" means an individual, general partnership, limited partnership, limited liability company, trust, estate, association, corporation, cooperative or any other legal or commercial entity;
- 16. "Flower" means the reproductive organs of the marijuana or cannabis plant referred to as the bud or parts of the plant that are harvested and used to consume in a variety of medical marijuana products;

17. "Flowering" means the reproductive state of the marijuana or cannabis plant in which there are physical signs of flower or budding out of the nodes of the stem;

1

2

3

4

5

6

7

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- 18. "Food-based medical marijuana concentrate" means a medical marijuana concentrate that was produced by extracting cannabinoids from medical marijuana through the use of propylene glycol, glycerin, butter, olive oil, coconut oil or other typical food-safe cooking fats;
- 19. "Good cause" for purposes of an initial, renewal or reinstatement license application, or for purposes of discipline of a licensee, means:
  - a. the licensee or applicant has violated, does not meet, or has failed to comply with any of the terms, conditions or provisions of the act, any rules promulgated pursuant thereto, or any supplemental relevant state or local law, rule or regulation,
  - b. the licensee or applicant has failed to comply with any special terms or conditions that were placed upon the license pursuant to an order of the State Department of Health, Oklahoma Medical Marijuana Authority or the municipality, or
  - c. the licensed premises of a medical marijuana business or applicant have been operated in a manner that adversely affects the public health or welfare or the

safety of the immediate vicinity in which the establishment is located;

- 20. "Harvest batch" means a specifically identified quantity of medical marijuana that is uniform in strain, cultivated utilizing the same cultivation practices, harvested at the same time from the same location and cured under uniform conditions;
- 21. "Harvested marijuana" means post-flowering medical marijuana not including trim, concentrate or waste;
- 22. "Heat- or pressure-based medical marijuana concentrate" means a medical marijuana concentrate that was produced by extracting cannabinoids from medical marijuana through the use of heat or pressure;
- 23. "Immature plant" means a nonflowering marijuana plant that has not demonstrated signs of flowering;
- 24. "Inventory tracking system" means the required tracking system that accounts for medical marijuana from either the seed or immature plant stage until the medical marijuana or medical marijuana product is sold to a patient at a medical marijuana dispensary, transferred to a medical marijuana research facility, destroyed by a medical marijuana business or used in a research project by a medical marijuana research facility;
- 25. "Licensed patient" or "patient" means a person who has been issued a medical marijuana patient license by the State Department of Health or Oklahoma Medical Marijuana Authority;

- 1 26. "Licensed premises" means the premises specified in an 2 application for a medical marijuana business license, medical marijuana research facility license or medical marijuana education 3 facility license pursuant to the Oklahoma Medical Marijuana and 5 Patient Protection Act that are owned or in possession of the licensee and within which the licensee is authorized to cultivate, 6 manufacture, distribute, sell, store, transport, test or research medical marijuana or medical marijuana products in accordance with 9 the provisions of the Oklahoma Medical Marijuana and Patient Protection Act and rules promulgated pursuant thereto; 10
  - 27. "Manufacture" means the production, propagation, compounding or processing of a medical marijuana product, excluding marijuana plants, either directly or indirectly by extraction from substances of natural or synthetic origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis;
  - defined in Section 2-101 of this title and shall not include any
    plant or material containing delta-8 or delta-10

    tetrahydrocannabinol which is grown, processed or sold pursuant to
    the provisions of the Oklahoma Industrial Hemp Program;

"Marijuana" shall have the same meaning as such term is

29. "Material change" means any change that would require a substantive revision to the standard operating procedures of a

11

12

13

14

15

16

17

18

19

20

21

22

- 1 licensee for the cultivation or production of medical marijuana,
  2 medical marijuana concentrate or medical marijuana products;
- 3 30. "Mature plant" means a harvestable female marijuana plant that is flowering;
  - 31. "Medical marijuana business (MMB)" means a licensed medical marijuana dispensary, medical marijuana processor, medical marijuana commercial grower, medical marijuana laboratory, medical marijuana business operator or a medical marijuana transporter;
  - 32. "Medical marijuana concentrate" or "concentrate" means a specific subset of medical marijuana that was produced by extracting cannabinoids from medical marijuana. Categories of medical marijuana concentrate include water-based medical marijuana concentrate, food-based medical marijuana concentrate, solvent-based medical marijuana concentrate, and heat- or pressure-based medical marijuana concentrate;
  - 33. "Medical marijuana commercial grower" or "commercial grower" means an entity licensed to cultivate, prepare and package medical marijuana and transfer or contract for transfer medical marijuana to a medical marijuana dispensary, medical marijuana processor, any other medical marijuana commercial grower, medical marijuana research facility, medical marijuana education facility and pesticide manufacturers. A commercial grower may sell seeds, flower or clones to commercial growers pursuant to the Oklahoma Medical Marijuana and Patient Protection Act;

- 34. "Medical marijuana education facility" or "education facility" means a person or entity approved pursuant to the Oklahoma Medical Marijuana and Patient Protection Act to operate a facility providing training and education to individuals involving the cultivation, growing, harvesting, curing, preparing, packaging or testing of medical marijuana, or the production, manufacture, extraction, processing, packaging or creation of medical-marijuana-infused products or medical marijuana products as described in the Oklahoma Medical Marijuana and Patient Protection Act;
- 35. "Medical-marijuana-infused product" means a product infused with medical marijuana including, but not limited to, edible products, ointments and tinctures;
- 36. "Medical marijuana product" or "product" means a product that contains cannabinoids that have been extracted from plant material or the resin therefrom by physical or chemical means and is intended for administration to a qualified patient including, but not limited to, oils, tinctures, edibles, pills, topical forms, gels, creams, vapors, patches, liquids and forms administered by a nebulizer, excluding live plant forms which are considered medical marijuana;
- 37. "Medical marijuana processor" means a person or entity licensed pursuant to the Oklahoma Medical Marijuana and Patient Protection Act to operate a business including the production, manufacture, extraction, processing, packaging or creation of

- 1 concentrate, medical-marijuana-infused products or medical marijuana
  2 products as described in the Oklahoma Medical Marijuana and Patient
  3 Protection Act;
  - 38. "Medical marijuana research facility" or "research facility" means a person or entity approved pursuant to the Oklahoma Medical Marijuana and Patient Protection Act to conduct medical marijuana research. A medical marijuana research facility is not a medical marijuana business;
    - 39. "Medical marijuana testing laboratory" or "laboratory" means a public or private laboratory licensed pursuant to the Oklahoma Medical Marijuana and Patient Protection Act, to conduct testing and research on medical marijuana and medical marijuana products;
    - 40. "Medical marijuana transporter" or "transporter" means a person or entity that is licensed pursuant to the Oklahoma Medical Marijuana and Patient Protection Act. A medical marijuana transporter does not include a medical marijuana business that transports its own medical marijuana, medical marijuana concentrate or medical marijuana products to a property or facility adjacent to or connected to the licensed premises if the property is another licensed premises of the same medical marijuana business;
    - 41. "Medical marijuana waste" or "waste" means unused, surplus, returned or out-of-date marijuana, plant debris of the plant of the genus Cannabis including dead plants and all unused plant parts and

1 roots, except the term shall not include roots, stems, stalks and 2 fan leaves;

- 42. "Medical use" means the acquisition, possession, use, delivery, transfer or transportation of medical marijuana, medical marijuana products, medical marijuana devices or paraphernalia relating to the administration of medical marijuana to treat a licensed patient;
- 8 43. "Mother plant" means a marijuana plant that is grown or
  9 maintained for the purpose of generating clones, and that will not
  10 be used to produce plant material for sale to a medical marijuana
  11 processor or medical marijuana dispensary;
  - 44. "Oklahoma physician" or "physician" means a physician licensed by and in good standing with the State Board of Medical Licensure and Supervision, the State Board of Osteopathic Examiners or the Board of Podiatric Medical Examiners;
  - 45. "Oklahoma resident" means an individual who can provide proof of residency as required by the Oklahoma Medical Marijuana and Patient Protection Act;
  - 46. "Owner" means, except where the context otherwise requires, a direct beneficial owner including, but not limited to, all persons or entities as follows:
    - a. all shareholders owning an interest of a corporate entity and all officers of a corporate entity,
    - b. all partners of a general partnership,

1 C. all general partners and all limited partners that own an interest in a limited partnership, 2 d. all members that own an interest in a limited 3 4 liability company, all beneficiaries that hold a beneficial interest in a 5 е. trust and all trustees of a trust, 6 f. all persons or entities that own interest in a joint 7 8 venture, 9 all persons or entities that own an interest in an g. association, 10 the owners of any other type of legal entity, and 11 h. any other person holding an interest or convertible 12 i. note in any entity which owns, operates or manages a 13 licensed facility; 14 47. "Package" or "packaging" means any container or wrapper 15 that may be used by a medical marijuana business to enclose or 16 contain medical marijuana; 17 "Person" means a natural person, partnership, association, 18 business trust, company, corporation, estate, limited liability 19 company, trust or any other legal entity or organization, or a 20 manager, agent, owner, director, servant, officer or employee 21 thereof, except that "person" does not include any governmental 22

organization;

23

49. "Pesticide" means any substance or mixture of substances intended for preventing, destroying, repelling or mitigating any pest or any substance or mixture of substances intended for use as a plant regulator, defoliant or desiccant, except that the term "pesticide" shall not include any article that is a "new animal drug" as designated by the United States Food and Drug Administration;

## 50. "Production batch" means:

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- a. any amount of medical marijuana concentrate of the same category and produced using the same extraction methods, standard operating procedures and an identical group of harvest batch of medical marijuana, or
- b. any amount of medical marijuana product of the same exact type, produced using the same ingredients, standard operating procedures and the same production batch of medical marijuana concentrate;
- 51. "Public institution" means any entity established or controlled by the federal government, state government, or a local government or municipality including, but not limited to, institutions of higher education or related research institutions;
- 52. "Public money" means any funds or money obtained by the holder from any governmental entity including, but not limited to, research grants;

53. "Recommendation" means a document that is signed or electronically submitted by a physician on behalf of a patient for the use of medical marijuana pursuant to the Oklahoma Medical Marijuana and Patient Protection Act;

- 54. "Registered to conduct business" means a person that has provided proof that the business applicant is in good standing with the Oklahoma Secretary of State and Oklahoma Tax Commission;
- 55. "Remediation" means the process by which the medical marijuana flower or trim, which has failed microbial testing, is processed into solvent-based medical marijuana concentrate and retested as required by the Oklahoma Medical Marijuana and Patient Protection Act;
- 56. "Research project" means a discrete scientific endeavor to answer a research question or a set of research questions related to medical marijuana and is required for a medical marijuana research license. A research project shall include a description of a defined protocol, clearly articulated goals, defined methods and outputs, and a defined start and end date. The description shall demonstrate that the research project will comply with all requirements in the Oklahoma Medical Marijuana and Patient Protection Act and rules promulgated pursuant thereto. All research and development conducted by a medical marijuana research facility shall be conducted in furtherance of an approved research project;

57. "Revocation" means the final decision by the Department that any license issued pursuant to the Oklahoma Medical Marijuana and Patient Protection Act is rescinded because the individual or entity does not comply with the applicable requirements set forth in the Oklahoma Medical Marijuana and Patient Protection Act or rules promulgated pursuant thereto;

- 58. "School" means a public or private preschool or a public or private elementary or secondary school which is primarily used for classroom instruction. A homeschool, daycare or child-care facility shall not be considered a "school" as used in the Oklahoma Medical Marijuana and Patient Protection Act;
- 59. "Shipping container" means a hard-sided container with a lid or other enclosure that can be secured in place. A shipping container is used solely for the transport of medical marijuana, medical marijuana concentrate, or medical marijuana products between medical marijuana businesses, a medical marijuana research facility, or a medical marijuana education facility;
- 60. "Solvent-based medical marijuana concentrate" means a medical marijuana concentrate that was produced by extracting cannabinoids from medical marijuana through the use of a solvent approved by the Department;
- 61. "State Question" means Oklahoma State Question No. 788, Initiative Petition No. 412, approved by a majority vote of the citizens of Oklahoma on June 26, 2018;

62. "Strain" means the classification of marijuana or cannabis plants in either pure sativa, indica, afghanica, ruderalis or hybrid varieties;

- 63. "THC" means tetrahydrocannabinol, which is the primary psychotropic cannabinoid in marijuana formed by decarboxylation of naturally tetrahydrocannabinolic acid, which generally occurs by exposure to heat;
- 64. "Test batch" means with regard to usable marijuana, a homogenous, identified quantity of usable marijuana by strain, no greater than ten (10) pounds, that is harvested during a seven-day period from a specified cultivation area, and with regard to oils, vapors and waxes derived from usable marijuana, means an identified quantity that is uniform, that is intended to meet specifications for identity, strength and composition, and that is manufactured, packaged and labeled during a specified time period according to a single manufacturing, packaging and labeling protocol;
- 65. "Transporter agent" means a person who transports medical marijuana or medical marijuana products for a licensed transporter and holds a transporter agent license pursuant to the Oklahoma Medical Marijuana and Patient Protection Act;
- 66. "Universal symbol" means the image established by the State

  Department of Health or Oklahoma Medical Marijuana Authority and

  made available to licensees through its website indicating that the

  medical marijuana or the medical marijuana product contains THC;

1	67. "Usable marijuana" means the dried leaves, flowers, oils,
2	vapors, waxes and other portions of the marijuana plant and any
3	mixture or preparation thereof, excluding seeds, roots, stems,
4	stalks and fan leaves; and
5	68. "Water-based medical marijuana concentrate" means a
6	concentrate that was produced by extracting cannabinoids from
7	medical marijuana through the use of only water, ice or dry ice.
8	SECTION 4. This act shall become effective November 1, 2022.
9	COMMITTEE REPORT BY: COMMITTEE ON BUSINESS, COMMERCE AND TOURISM February 17, 2022 - DO PASS
10	representative transfer and tra
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	